mexiletine has been researched along with Epilepsy, Absence in 1 studies
Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.
mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.
Epilepsy, Absence: A seizure disorder usually occurring in childhood characterized by rhythmic electrical brain discharges of generalized onset. Clinical features include a sudden cessation of ongoing activity usually without loss of postural tone. Rhythmic blinking of the eyelids or lip smacking frequently accompanies the SEIZURES. The usual duration is 5-10 seconds, and multiple episodes may occur daily. Juvenile absence epilepsy is characterized by the juvenile onset of absence seizures and an increased incidence of myoclonus and tonic-clonic seizures. (Menkes, Textbook of Child Neurology, 5th ed, p736)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The treatment with lidocaine followed by mexiletine was useful for controlling clusters of intractable seizures." | 5.30 | [A successful treatment with intravenous lidocaine followed by oral mexiletine in a patient with Lennox-Gastaut syndrome]. ( Miyamoto, A; Oki, J; Takahashi, S, 1999) |
| "The treatment with lidocaine followed by mexiletine was useful for controlling clusters of intractable seizures." | 1.30 | [A successful treatment with intravenous lidocaine followed by oral mexiletine in a patient with Lennox-Gastaut syndrome]. ( Miyamoto, A; Oki, J; Takahashi, S, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Miyamoto, A | 1 |
| Takahashi, S | 1 |
| Oki, J | 1 |
1 other study available for mexiletine and Epilepsy, Absence
| Article | Year |
|---|---|
[A successful treatment with intravenous lidocaine followed by oral mexiletine in a patient with Lennox-Gastaut syndrome].
Topics: Administration, Oral; Adolescent; Epilepsies, Myoclonic; Epilepsy, Absence; Epilepsy, Generalized; H | 1999 |